Why the study?
Does fixed-dose combination therapy improve medication adherence in patients with or at high risk for cardiovascular disease?
Does fixed-dose combination therapy improve medication adherence in patients with or at high risk for cardiovascular disease?
While fixed-dose combination therapy significantly improves medication adherence, widespread adoption for secondary cardiovascular prevention requires long-term outcome trials and updated formulations.
Mark Huffman asks what happened to the polypill to reduce cardiovascular risk, explores the promise it still holds, and considers how best to turn promise into reality.
No takes yet. Share an insight, caveat, or question.
Mark D. Huffman (2015) conducted a review in cardiovascular disease (n=3,338). Fixed-dose combination therapy vs. usual care was evaluated on adherence (RR 1.44, 95% CI 1.26-1.65).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: